<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-5 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-5</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-5</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <p><strong>Paper ID:</strong> paper-6ef03357dab851c0cb28d71e6e48136adeba70c4</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/6ef03357dab851c0cb28d71e6e48136adeba70c4" target="_blank">Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Immunology</p>
                <p><strong>Paper TL;DR:</strong> This reported case demonstrates that neo-adjuvant systemic immunotherapy with ipilimumab and nivolumab could also be effective in mucosal melanoma despite of its generally lower response to immunotherapy.</p>
                <p><strong>Paper Abstract:</strong> Melanoma causes the majority of skin cancer-related deaths. Despite novel therapy options, metastatic melanoma still has a poor prognosis. Immune checkpoint inhibition (ICI) therapy has been shown to prolong overall survival in patients with advanced melanoma, but mucosal melanomas respond less favorably compared to melanomas of cutaneous origin. We report on a patient with a mucosal melanoma of the rectum diagnosed in June 2020. Since a surgical intervention in order to achieve a tumor-free situation would have required an amputation of the rectum, a neo-adjuvant systemic immunotherapy with ipilimumab and nivolumab was initiated. As restaging and colonoscopy after four doses of this combination immunotherapy showed a partial response, the patient decided against the pre-planned surgery and a maintenance therapy with nivolumab was started. Repeated colonoscopy showed a complete response after four doses of nivolumab. After ongoing ICI therapy with nivolumab and no evidence of tumor relapse, immunotherapy was stopped in July 2022 after nearly 2 years of continuous treatment. The patient remained tumor-free during further follow-up. Neo-adjuvant immunotherapy is getting more explored in advanced melanoma. By administering ICI therapy before surgical resection of an essentially operable tumor, a stronger and more diverse immunological response is supposed to be achieved. Our reported case demonstrates that this approach could also be effective in mucosal melanoma despite of its generally lower response to immunotherapy.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e5.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e5.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Blank et al. 2018</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Study reported favorable response and survival outcomes when ipilimumab plus nivolumab was given in a neoadjuvant versus an adjuvant setting for patients with macroscopic stage III cutaneous melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Comparison of neoadjuvant versus adjuvant administration of ipilimumab plus nivolumab in macroscopic stage III melanoma (as reported by Blank et al.).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Ipilimumab plus nivolumab given in neoadjuvant timing versus adjuvant timing; exact dosing and schedule not provided in this case report.</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Macroscopic stage III cutaneous melanoma patients; sample size not reported in the present paper.</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td>Reported favorable response and survival outcomes for the neoadjuvant ipilimumab + nivolumab strategy compared with adjuvant timing (no quantitative data provided in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td>Neoadjuvant ICI is hypothesized to generate a stronger and more diverse antitumor immune response by treating while the intact tumor is present.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab', 'publication_date_yy_mm': '2024-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e5.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e5.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Patel et al. 2023</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Study comparing a combined neoadjuvant followed by adjuvant pembrolizumab regimen versus adjuvant-only pembrolizumab in resectable stage III/IV cutaneous melanoma, reporting a higher proportion of patients achieving 2â€‘year event-free survival in the combined (neoadjuvant+adjuvant) arm.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Head-to-head comparison of combined neoadjuvant then adjuvant pembrolizumab versus adjuvant-only pembrolizumab in resectable advanced melanoma (as reported by Patel et al.).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Pembrolizumab administered either as a neoadjuvant course followed by adjuvant pembrolizumab, or as adjuvant-only pembrolizumab; specific dosing/schedule not reported in this case report.</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable stage III/IV cutaneous melanoma; exact sample size not reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Reported: higher proportion of patients achieved 2-year event-free survival with combined neoadjuvant+adjuvant pembrolizumab versus adjuvant-only pembrolizumab (numerical values not given in this case report).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td>Combined neoadjuvant followed by adjuvant pembrolizumab associated with improved 2-year event-free survival versus adjuvant-only pembrolizumab (no detailed effect size reported here).</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td>Authors and the case report cite the general hypothesis that pre-surgical ICI primes a stronger/diversified immune response by exposing the immune system to tumor antigens while the tumor is present.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab', 'publication_date_yy_mm': '2024-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e5.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e5.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NCT04949113 (phase 3 trial)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Ongoing phase 3 clinical trial mentioned in this paper comparing neoadjuvant ipilimumab + nivolumab versus adjuvant nivolumab monotherapy in stage III cutaneous or unknown primary melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>NCT04949113</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase 3 clinical trial comparing a neoadjuvant combination (ipilimumab + nivolumab) with adjuvant nivolumab monotherapy in stage III cutaneous/unknown primary melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Neoadjuvant ipilimumab + nivolumab (combination) versus adjuvant nivolumab monotherapy; dosing and schedule not provided in this case report.</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Stage III cutaneous or unknown primary melanoma patients; sample size not specified in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td>Implicit: neoadjuvant administration may elicit stronger/diverse antitumor immunity by treating with intact tumor present.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab', 'publication_date_yy_mm': '2024-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e5.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e5.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Amaria et al. 2022</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant relatlimab and nivolumab in resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Report of a perioperative/neoadjuvant regimen combining nivolumab with the LAG-3 inhibitor relatlimab in resectable melanoma; cited as a successful perioperative treatment regimen similar to other neoadjuvant approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant relatlimab and nivolumab in resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Neoadjuvant/perioperative study of combination nivolumab + relatlimab in resectable melanoma (details not provided in this case report).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Nivolumab combined with relatlimab used in a neoadjuvant/perioperative context; dosing/schedule not provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable melanoma patients; sample size not stated in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td>Consistent with the general neoadjuvant rationale that pre-surgical checkpoint inhibition can prime enhanced antitumor immunity.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab', 'publication_date_yy_mm': '2024-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e5.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e5.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Menzies et al. 2021 (INMC pooled analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Pooled analysis reporting pathological response and survival after neoadjuvant therapy in melanoma; concluded that tumor responses were more durable after neoadjuvant immunotherapy (notably ipilimumab + nivolumab) than after neoadjuvant BRAF/MEK targeted therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Pooled analysis of multiple neoadjuvant melanoma trials collated by the International Neoadjuvant Melanoma Consortium (INMC).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Various neoadjuvant regimens analyzed, including immune checkpoint combinations (e.g., ipilimumab + nivolumab) and neoadjuvant BRAF/MEK inhibition; specific regimens vary across pooled studies.</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable stage III melanoma across multiple trials (exact combined sample size not provided in this case report).</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td>Reported pathological responses and survival outcomes across neoadjuvant studies; the pooled analysis found neoadjuvant immunotherapy (particularly ipilimumab + nivolumab) produced more durable tumor responses than neoadjuvant BRAF/MEK inhibition (no specific percentages provided in this case report).</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td>Neoadjuvant immunotherapy yielded more durable tumor responses than neoadjuvant targeted BRAF/MEK therapy in the pooled analysis; direct comparisons to adjuvant-only approaches are not detailed in this case report.</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td>Consistent with the hypothesis that pre-operative immune checkpoint blockade elicits stronger/diverse antitumor immunity when the tumor is present.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab', 'publication_date_yy_mm': '2024-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma <em>(Rating: 2)</em></li>
                <li>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma <em>(Rating: 2)</em></li>
                <li>Neoadjuvant relatlimab and nivolumab in resectable melanoma <em>(Rating: 1)</em></li>
                <li>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) <em>(Rating: 2)</em></li>
                <li>Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>